The FDA is expected to decide on treatments for ADHD, Alzheimer disease, breast cancer, diabetes, and myasthenia gravis.

A unanimous United States Supreme Court decision has now removed a significant procedural hurdle for medical malpractice plaintiffs in 28 states. In this case, the Court was asked to determine whether ...

The TEPEZZA OBI trial evaluated the safety and efficacy of SC teprotumumab in patients with active TED and proptosis of 3mm or greater from baseline.

More than tripled risk of five-year mortality seen with use of complementary and alternative medicine alone compared with traditional therapies.

The new advice comes as federal dietary guidance has taken a much different stance. Health officials, alongside US Health Secretary Robert F. Kennedy Jr., have suggested people can include more red ...

Incidence of primary end point lower for patients with target LDL level less than 55mg/dL vs less than 70mg/dL.

HealthDay News — Glucagon-like peptide-1 (GLP-1) receptor agonist (RA) use is associated with delayed wound healing in patients undergoing abdominal panniculectomy, according to a study published in ...

Discontinuing β-blockers after one year or longer is noninferior for all-cause death, recurrent MI, or hospitalization for heart failure.

The Food and Drug Administration (FDA) has approved extended dosing intervals for Eylea HD ® (aflibercept) for patients with wet age-related macular degeneration (wAMD) and diabetic macular edema (DME ...

Expanding eligibility for full LIS to include Medicare beneficiaries with incomes between 135 and 150 percent of FPL reduces cost-related medication nonadherence ...

Participants did demonstrate greater proptosis improvement from baseline following the initial high dose period vs after the ...

The table below is a review of notable updates that occurred in March 2026 for investigational products in development (not an inclusive list). Click on the status to view our full coverage.